Annals of vascular surgery · 2026
Impact of Prophylactic Postoperative Vasopressors on Outcomes of Patients Undergoing Thoracic Endovascular Aortic Repair.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Veranyan Narek, Yei Kevin, Ilyas Sadia, Wang Sophie X, Beck Adam W, Malas Mahmoud B
Аннотация
BACKGROUND: Prophylactic postoperative vasopressors (PPVs) are used to induce hemodynamic augmentation to prevent spinal cord ischemia (SCI) in patients undergoing thoracic endovascular aortic repair (TEVAR). However, the scientific evidence on its effectiveness and safety is limited. This study aims to investigate the safety and effectiveness of PPV in patients undergoing TEVAR in a multi-institutional real-world setting.
METHODS: All TEVAR patients in the Society for Vascular Surgery Vascular Quality Initiative database between March 1, 2012, and January 28, 2023, were identified. Univariable and multivariable analyses were performed to assess the association between the use of PPV and the rates of postoperative 30-day mortality, major adverse cardiovascular events (MACE, defined as new onset of postoperative myocardial infarction, congestive heart failure, dysrhythmias, or stroke), SCI, and other adverse events for patients undergoing TEVAR.
RESULTS: Out of 25,549 reviewed patients, 11,342 underwent TEVAR, matching the study criteria, and were analyzed. A total of 2,420 patients (21.3%) received PPV. Patients who received PPV had significantly higher rates of 30-day mortality (9.3% vs. 2.1%, P < 0.001), MACE (18.2% vs. 7.4%, P < 0.001), postoperative SCI (2.6% vs. 1.3%, P < 0.001), and other adverse events. After adjusting for confounders, the use of PPV was associated with significantly increased odds of 30-day mortality (odds ratio [OR], 3.23, 95% confidence interval [CI]: 2.58-4.04, P < 0.001), MACE (OR, 2.18, 95% CI: 1.89-2.51, P < 0.001), postoperative SCI (OR, 1.46, 95% CI: 1.05-2.01, P = 0.022), and other adverse events.
CONCLUSION: PPV was associated with significantly higher odds of 30-day mortality, MACE, SCI, and other adverse outcomes. The role of PPV should be re-evaluated, and the decision for administration should be made on an individualized basis, considering patient comorbidities and risk factors. A prospective study is required to confirm these findings.
METHODS: All TEVAR patients in the Society for Vascular Surgery Vascular Quality Initiative database between March 1, 2012, and January 28, 2023, were identified. Univariable and multivariable analyses were performed to assess the association between the use of PPV and the rates of postoperative 30-day mortality, major adverse cardiovascular events (MACE, defined as new onset of postoperative myocardial infarction, congestive heart failure, dysrhythmias, or stroke), SCI, and other adverse events for patients undergoing TEVAR.
RESULTS: Out of 25,549 reviewed patients, 11,342 underwent TEVAR, matching the study criteria, and were analyzed. A total of 2,420 patients (21.3%) received PPV. Patients who received PPV had significantly higher rates of 30-day mortality (9.3% vs. 2.1%, P < 0.001), MACE (18.2% vs. 7.4%, P < 0.001), postoperative SCI (2.6% vs. 1.3%, P < 0.001), and other adverse events. After adjusting for confounders, the use of PPV was associated with significantly increased odds of 30-day mortality (odds ratio [OR], 3.23, 95% confidence interval [CI]: 2.58-4.04, P < 0.001), MACE (OR, 2.18, 95% CI: 1.89-2.51, P < 0.001), postoperative SCI (OR, 1.46, 95% CI: 1.05-2.01, P = 0.022), and other adverse events.
CONCLUSION: PPV was associated with significantly higher odds of 30-day mortality, MACE, SCI, and other adverse outcomes. The role of PPV should be re-evaluated, and the decision for administration should be made on an individualized basis, considering patient comorbidities and risk factors. A prospective study is required to confirm these findings.
Предметные рубрики MeSH
HumansFemaleEndovascular Aneurysm RepairRisk FactorsTreatment OutcomeTime FactorsMaleAgedRisk AssessmentAorta, ThoracicDatabases, FactualRetrospective StudiesVasoconstrictor AgentsMiddle AgedAged, 80 and overBlood Vessel Prosthesis ImplantationSpinal Cord IschemiaAortic DiseasesEndovascular Procedures